Olon USA’s global leadership in Milan, Italy has officially announced the completion of a major expansion at its Concord, Ohio facility, marking a significant step forward for their U.S. manufacturing capabilities and its integrated global API network.
[Read the full press release here.]
For Olon USA, this news represents much more than additional production capacity. It signals the continued evolution of Concord from a site historically known for R&D, chemical synthesis, process development, and early-stage manufacturing into something much broader: a fully integrated U.S. development and commercial manufacturing hub backed by the strength of Olon’s global network.
That distinction matters.
Today’s pharmaceutical and biotechnology companies are asking different questions than they were just a few years ago. They are not only evaluating technical capability or available capacity. They are asking where their APIs will be manufactured, how resilient their supply chain will be, and whether their CDMO partner can support them from early development through commercial production without unnecessary handoffs or disruption.
With the completion of this expansion, Olon USA is positioned to answer those questions with greater confidence than ever before.
More Than Additional Capacity
The official announcement confirms that the expansion doubles production capacity at the Concord site. That is an important milestone, but it is only part of the story.
For Robert Poe, CEO of Olon USA, the larger significance is what this expansion enables for customers.
“This really gives customers confidence that we can handle their program not only during early development,” Poe explained, “but through Phase III and potentially into commercial production.”
That continuity is increasingly valuable in pharmaceutical development. Every transition between organizations can introduce new risk, additional technology transfer, and potential delays. By expanding Concord’s commercial manufacturing capabilities while preserving its established development expertise, Olon USA gives customers the ability to work with a single, deeply integrated partner across more of the product lifecycle.
A U.S. Manufacturing Hub Backed by Global Strength
Concord’s role within Olon has changed significantly since the site was acquired in 2017. What was once primarily an R&D-focused operation has steadily evolved into a stronger, more mature, more commercially capable organization.
That transformation has been supported by investment in people, infrastructure, quality systems, environmental health and safety, analytical chemistry, quality control, and operations. The result is a site that can serve customers locally while drawing from the broader expertise of Olon’s global organization.
For customers, that combination is powerful.
Working with Olon USA means access to U.S.-based API development and manufacturing capabilities, while also benefiting from the regulatory knowledge, scientific resources, and technical depth of a global CDMO with manufacturing and R&D operations around the world.
Why U.S.-Based API Manufacturing Matters Now
The timing of this expansion is also important.
Across the pharmaceutical industry, companies are rethinking supply chain strategy. Government funding requirements, reshoring initiatives, geopolitical uncertainty, and lessons learned during the pandemic have all increased demand for reliable U.S.-based API manufacturing.
“We continue to talk with companies that need U.S. supply chain capabilities for their commercial drugs,” Poe said. “Whether they are supported by government funding, Department of Defense contracts, or simply looking to strengthen their domestic manufacturing strategy, many organizations are actively moving API synthesis into the United States.”
And that need is unlikely to fade.
For pharmaceutical companies developing or commercializing products in the United States, domestic manufacturing can provide greater control, improved continuity, and additional confidence in long-term supply.
Olon’s expanded Concord facility helps meet that need by offering U.S.-based manufacturing capacity within a globally connected organization.
Strengthening the Bridge from Development to Commercial Supply
One of the most important advantages of the Concord expansion is the way it strengthens the bridge between development and commercialization.
Early-stage process development requires scientific creativity, flexibility, and problem-solving. Commercial manufacturing requires disciplined execution, quality systems, regulatory readiness, and operational consistency. The best CDMO partners understand both worlds and can help customers move between them with less friction.
That is where Concord’s evolution is especially meaningful.
The site is not stepping away from its R&D roots. Instead, it is building upon them. Customers can still rely on Olon USA for process development, scale-up, analytical support, and early manufacturing, but now with an even stronger path toward later-stage and commercial production.
That creates a more complete end-to-end solution for companies looking to reduce variability, protect timelines, and maintain program continuity.
Investment in Quality, People, and Long-Term Stability
Commercial manufacturing is not created by equipment alone.
It requires experienced people, disciplined systems, and a culture that understands the expectations of regulated pharmaceutical production.
As part of Concord’s expansion, Olon USA has added new roles across nearly every department, including operators, quality personnel, analytical chemistry, quality control, and operations leadership. Poe noted that the expansion is expected to bring approximately twenty-seven new jobs to the area, reinforcing the company’s commitment not only to customers, but also to the Concord community.
The investment also reflects a deeper level of long-term stability for the site.
Concord is firmly positioned as a strategic part of Olon’s global growth strategy. For employees, that creates confidence and stability. For customers, it signals commitment, continuity, and a partner prepared to support programs for the long term.
A Connected Global Organization with Local Manufacturing Strength
The press release also highlights Concord’s closer integration with Olon’s European operations. In practical terms, that integration gives customers access to a broader range of expertise while maintaining the advantages of U.S.-based execution.
Olon USA can draw from global regulatory, technical, quality, engineering, and manufacturing resources as needed. That means customers are not working with an isolated site. They are working with a connected organization capable of supporting increasingly complex development and manufacturing challenges across regions.
For companies evaluating API partners, this offers an important balance: the responsiveness and strategic value of U.S. manufacturing, supported by the depth and scale of a global CDMO.
Looking Ahead
The completion of the Concord expansion is a major milestone, but it is also part of a larger story.
Olon USA is continuing to strengthen its role as a U.S. development and commercial manufacturing hub, while Olon Group continues to build a more agile, integrated, and globally connected organization.
For customers, the message is clear.
Olon USA is no longer simply an R&D site within a global network. Concord is now a strategic U.S. hub for API development, scale-up, and commercial manufacturing, supported by the people, systems, infrastructure, and global expertise needed to help pharmaceutical programs move forward with confidence.
As demand for domestic manufacturing, resilient supply chains, and integrated CDMO partnerships continues to grow, Olon’s investment in Concord positions the site to play an even larger role in the future of U.S. pharmaceutical manufacturing.